Sleep Group Opposes Medical Cannabis for Sleep Apnea | IUK Med Online
Wednesday, July 18, 2018
Home Medical News Sleep Group Opposes Medical Cannabis for Sleep Apnea

Sleep Group Opposes Medical Cannabis for Sleep Apnea

18
0
SHARE


Medpage Today

Sleep Group Opposes Medical Cannabis for Sleep Apnea

AASM cites insufficient evidence of efficacy, safety

MedpageToday

The nation’s leading sleep medicine group is opposing the use of medical cannabis and synthetic marijuana extracts for the treatment of obstructive sleep apnea (OSA).

Late last year, the Minnesota Department of Health announced that OSA would be added to the state’s medical cannabis program list of chronic medical conditions.

But in a newly published position statement, the American Academy of Sleep Medicine (AASM) took issue with the move, concluding that OSA should be excluded from all state medical cannabis programs lists due to unreliable cannabis delivery methods and “insufficient evidence of treatment effectiveness, tolerability and safety.”

The position statement was published in the April 15 issue of the AASM’s Journal of Clinical Sleep Medicine.

“Until there is sufficient scientific evidence of safety and efficacy, neither marijuana nor synthetic medical cannabis should be used for the treatment of sleep apnea,” AASM president Ilene Rosen, MD, noted in a press release.

The position statement, which was written by the AASM board of directors, called the Minnesota action on OSA “concerning” given that the research cited in the decision was limited to proof-of-concept and pilot studies.

“The duration of these studies was only 3-6 weeks, and therefore the long-term effects of use of these medical cannabis products and the effect on OSA is unknown at the time,” wrote sleep medicine specialist Kannan Ramar, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues. “Also, treatment with the use of medical cannabis has shown adverse effects such as daytime sleepiness and may lead to unintended consequences such as motor vehicle accidents.”

The statement noted that the studies to date have been largely confined to examining the impact of the synthetic cannabis extract dronabinol on sleep apnea symptoms.

“Dronabinol is one of the many synthetic medical cannabis extracts,” the board of directors noted. “The composition of cannabinoids within medical cannabis varies significantly and is not regulated. Therefore, synthetic medical cannabis may have differential CB1 and CB2 receptor effects, with variable efficacy and side effects in the treatment of OSA.”

The AASM is advising state legislators, regulators and health departments that obstructive sleep apnea should not be included as an indication for their medical cannabis programs.

Nearly 30 million adults in the United States have OSA.

The statement noted that there is a need for increased funding and further research on the use of synthetic medical cannabis extracts for the treatment of OSA.

“We need a better understanding of the pathophysiologic mechanisms on how synthetic medical cannabis extracts work differentially on the CB1 and CB2 receptors peripherally to help patients with OSA,” the position statement noted, adding that this research may identify other synthetic extracts with higher efficacy in the treatment of OSA and fewer side effects.

“Because of the potential for misuse and increased costs, the lack of evidence on beneficial effects, and risk of side effects including increased daytime sleepiness, which might lead to more harm than benefit, the AASM takes the position that medical cannabis should not be used for the treatment of OSA at this time,” the statement read.

1969-12-31T19:00:00-0500

last updated

Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.

Medpage Today

Sleep Group Opposes Medical Cannabis for Sleep Apnea

AASM cites insufficient evidence of efficacy, safety

MedpageToday

The nation's leading sleep medicine group is opposing the use of medical cannabis and synthetic marijuana extracts for the treatment of obstructive sleep apnea (OSA).

Late last year, the Minnesota Department of Health announced that OSA would be added to the state's medical cannabis program list of chronic medical conditions.

But in a newly published position statement, the American Academy of Sleep Medicine (AASM) took issue with the move, concluding that OSA should be excluded from all state medical cannabis programs lists due to unreliable cannabis delivery methods and "insufficient evidence of treatment effectiveness, tolerability and safety."

The position statement was published in the April 15 issue of the AASM's Journal of Clinical Sleep Medicine.

"Until there is sufficient scientific evidence of safety and efficacy, neither marijuana nor synthetic medical cannabis should be used for the treatment of sleep apnea," AASM president Ilene Rosen, MD, noted in a press release.

The position statement, which was written by the AASM board of directors, called the Minnesota action on OSA "concerning" given that the research cited in the decision was limited to proof-of-concept and pilot studies.

"The duration of these studies was only 3-6 weeks, and therefore the long-term effects of use of these medical cannabis products and the effect on OSA is unknown at the time," wrote sleep medicine specialist Kannan Ramar, MD, of the Mayo Clinic in Rochester, Minnesota, and colleagues. "Also, treatment with the use of medical cannabis has shown adverse effects such as daytime sleepiness and may lead to unintended consequences such as motor vehicle accidents."

The statement noted that the studies to date have been largely confined to examining the impact of the synthetic cannabis extract dronabinol on sleep apnea symptoms.

"Dronabinol is one of the many synthetic medical cannabis extracts," the board of directors noted. "The composition of cannabinoids within medical cannabis varies significantly and is not regulated. Therefore, synthetic medical cannabis may have differential CB1 and CB2 receptor effects, with variable efficacy and side effects in the treatment of OSA."

The AASM is advising state legislators, regulators and health departments that obstructive sleep apnea should not be included as an indication for their medical cannabis programs.

Nearly 30 million adults in the United States have OSA.

The statement noted that there is a need for increased funding and further research on the use of synthetic medical cannabis extracts for the treatment of OSA.

"We need a better understanding of the pathophysiologic mechanisms on how synthetic medical cannabis extracts work differentially on the CB1 and CB2 receptors peripherally to help patients with OSA," the position statement noted, adding that this research may identify other synthetic extracts with higher efficacy in the treatment of OSA and fewer side effects.

"Because of the potential for misuse and increased costs, the lack of evidence on beneficial effects, and risk of side effects including increased daytime sleepiness, which might lead to more harm than benefit, the AASM takes the position that medical cannabis should not be used for the treatment of OSA at this time," the statement read.

1969-12-31T19:00:00-0500

last updated

Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here